Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

Price Sensitive Information

30 Apr 2009 12:55

RNS Number : 4931R
Beximco Pharmaceuticals Ltd
30 April 2009
 



BEXIMCO PHARMACEUTICALS LTD.

30th April, 2009

PRICE SENSITIVE INFORMATION

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces information for Shareholders of the Company that the Board of Directors in their meeting held on 30th April, 2009 at 5.00 p.m. has decided the following: 

1. Revaluation of Assets of the Company: 

Accepted an independent report on the valuation of

Lands, Buildings, Plant and Machinery as of 31 December, 2008 issued by M/S S F Ahmed & Co. Chartered Accountants and Valuer showing an aggregate depreciated current cost of Tk 5,485,286,356 resulting in a revaluations surplus aggregating Tk 1,711,174,747

 

2. Date & Time of 33rd AGM of the: 

Company for the year 2008

 

16th June, 2009 at 9.30 a.m

3. Proposed Dividend:

10% Cash and 20% Stock dividend 

for the year ended 31 December 2008

 

4. Record date:

25th May, 2009.

 

5. Venue of AGM:

1 Shahbag C/A, DhakaBangladesh

 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan, CEO

MD. ASAD ULLAH, FCS, Company Secretary

Tel: +880 2 861 9151, ext.2080

 

Libertas Capital

Jakob Kinde / Anthony Rowland

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in DhakaBangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri LankaNepalBhutanVietnamCambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFBLFXKZBEBBX
Date   Source Headline
27th Dec 20177:00 amRNSAGM Statement
30th Nov 201710:30 amRNSBeximco Pharma wins at Scrip Awards 2017
23rd Nov 201711:53 amRNSNotice of AGM
14th Nov 20177:00 amRNSResults for First Quarter Ended 30 September 2017
7th Nov 20177:00 amRNSCommencement of Second Product Export to the US
6th Nov 201710:30 amRNSResults for the 12 month period ended 30 June 2017
26th Oct 20177:00 amRNSNotice of Preliminary Results and AGM
6th Oct 20177:00 amRNSSigns a Non-Binding MoU with Nuvista Pharma
2nd Oct 20177:00 amRNSChange of Broker
18th Sep 20177:00 amRNSCommences Export to Canada
25th Jul 20177:00 amRNSFDA approves Beximco Pharma Methocarbamol tablets
28th Apr 20177:00 amRNSFinancial Results for the Third Quarter of 2016-17
27th Jan 20177:00 amRNSHalf year results 2016-17
25th Jan 20177:00 amRNSBeximco Pharma forms JV with BioCare Manufacturing
19th Dec 20167:00 amRNSUS FDA approves Metformin for diabetes control
16th Dec 201610:12 amRNSPayment of Cash Dividend
12th Dec 20161:54 pmRNSStock Dividend Issued and Total Voting Rights
21st Nov 20167:00 amRNSAGM Statement
15th Nov 20167:00 amRNS1st Quarter Results
25th Oct 20167:00 amRNSReceives second product approval from the US FDA
20th Oct 20167:00 amRNSResults for the 18 month period ended 30 June 2016
19th Oct 20167:00 amRNSNotice of AGM
7th Oct 20167:00 amRNSNotification of Preliminary Results and AGM
5th Aug 20167:00 amRNSBeximco Pharma commences export to the US
17th Jun 20167:00 amRNSBeximco Pharma commences export to Kuwait
9th May 20167:00 amRNSFinal Results
6th May 20167:01 amRNSAGM Change and Dividend Update
6th May 20167:00 amRNSChange of Accounting Reference Date
4th May 20167:00 amRNSAmendment to Notification of Preliminary Results
21st Apr 20167:00 amRNSNotification of Preliminary Results and AGM
19th Nov 20157:00 amRNSUS FDA approval to manufacture blood pressure drug
27th Oct 20157:00 amRNS3rd Quarter Results
24th Jul 20157:00 amRNSHalf Yearly Report
13th Jul 201510:53 amRNSPayment of Cash Dividend
26th Jun 20157:00 amRNSStock Dividend Issued and Total Voting Rights
24th Jun 20157:00 amRNSBeximco Pharma receives US FDA approval
15th Jun 20157:00 amRNSAGM Statement
14th May 20157:00 amRNSFirst Quarter Results
12th May 20157:01 amRNSAGM Notification
11th May 20157:00 amRNSAnnual Financial Report
28th Apr 20157:00 amRNSNotification of Preliminary Results and AGM
2nd Feb 20157:00 amRNSBeximco Pharma completes US FDA Audit
28th Jan 20157:00 amRNSEnters into new Loan Agreement to fund expansion
19th Jan 201512:42 pmRNSBeximco Pharma commences export to Australia
12th Dec 20147:00 amRNSAppointment of Nominated Adviser
24th Nov 20147:00 amRNSReceives GMP Approval from Health Canada
3rd Nov 20147:00 amRNSBoard Appointment
30th Oct 20147:00 amRNSFinancial Results for the Third Quarter of 2014
24th Jul 20147:00 amRNSHalf Yearly Report
14th Jul 20143:44 pmRNSPayment of Cash Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.